Vaccines have played a crucial role in preventing infectious diseases for decades, leading to the control and eradication of numerous harmful pathogens. They have a profound impact on public health by significantly reducing illness, disability, and mortality rates worldwide. The importance of vaccines lies in their ability to activate the immune system to recognize and respond effectively to specific pathogens. By stimulating the production of antibodies and memory cells, vaccines strengthen the body's defense mechanism. This not only protects individuals who are immunized but also contributes to the development of herd immunity, safeguarding those who cannot be vaccinated due to certain medical conditions. While vaccines undergo rigorous testing and regulatory approval before introduction into the market, ongoing pharmacovigilance remains essential in monitoring their safety and promptly identifying any adverse events. Pharmacovigilance encompasses the processes of collecting, analyzing, and assessing data related to vaccines' safety profiles. This surveillance system enables the detection of rare or unexpected side effects, facilitating timely risk management strategies and ensuring public confidence in vaccination programs. Pharmacovigilance activities include passive reporting systems, active surveillance programs, and in-depth investigations of adverse events. Adverse events are thoroughly evaluated in terms of their causal relationship with the vaccine, the severity of the event, and the affected population groups. This report discusses Crucial role in public health by preventing the spread of infectious diseases, Different methods are used to monitor vaccines' safety and effectiveness, including post-marketing surveillance studies, spontaneous reporting systems, and active surveillance through various healthcare databases. 

One of the most effective methods for preventing and managing infectious diseases is vaccination. They function by inducing the production of antibodies and memory cells by the immune system, which are then able to identify and neutralise the microorganisms that cause disease. Immunisations can prevent the transmission of diseases and develop herd immunity, which can benefit both the recipients and the communities in which they reside. Vaccines do not, however, come without hazards or limitations. Certain vaccinations might not work for everyone or might become less effective over time. Some people may experience mild to severe adverse reactions or side effects from some immunisations. Certain vaccines may cause problems in terms of ethics or society, or they may interfere with other medications or medical conditions. Pharmacovigilance for vaccines entails gathering and examining information from a range of sources, including social media, databases, registries, post-marketing surveillance, spontaneous reporting systems, and clinical trials. It also entails informing the relevant parties—health authorities, vaccine producers, medical professionals, and members of the public—with the results and suggestions. The primary goals of vaccine pharmacovigilance are to guarantee the efficacy, safety, and quality of vaccines; to recognise and manage any possible risks or benefits; and to encourage the best possible use of vaccinations.

With the COVID-19 pandemic hastened the creation and introduction of new vaccinations against the novel coronavirus, pharmacovigilance of vaccines is particularly pertinent. The vaccine's unparalleled speed and scope

2.Definition of Vaccine: 

Vaccines are biological preparations that strengthen immunity against specific diseases, often given via needle injection or orally or sprayed into the nose. They mimic disease-causing bacteria and help the immune system recognize and eliminate foreign agents, enabling the body to recognize and destroy them. The term "vaccination" comes from cow smallpox. [1]          

3.Types: 

3.1. Live, Attenuated Vaccines: 

Live, attenuated vaccinations, such as those for chickenpox, mumps, and measles, are weakened copies of live germs in the lab that instruct the immune system on how to prevent illness. [2]

Example: Vaccines against measles, mumps, and chickenpox

3.2. Inactivated Vaccines

Scientists create inactivated vaccines by killing disease-causing microbes using chemicals, heat, or radiation, ensuring stability and safety over live vaccines as dead microbes cannot mutate. [2]

Example: Vaccines against influenza, polio, hepatitis A, and rabies. 2. Inactivated Vaccines:

3.3. Subunits Vaccines: 

Subunit vaccines contain essential antigens that stimulate the immune system, using specific epitopes for recognition and binding by antibodies or T cells. [2]

Example: Plague immunization.

3.4. Toxoid Vaccines: 

A toxoid vaccine is used for bacteria causing illness due to bacterial toxins. Toxoids, which can be inactivated with formalin, are safe for use in vaccines due to their detoxification properties. [2]

Example: Crotalus atrox toxoid is used to vaccinate dogs against rattlesnake bites.

3.5. Conjugate Vaccines:

Researchers may develop a conjugate vaccine for harmful bacteria with polysaccharide coatings, which disguise antigens, preventing immature immune systems from responding to them in infants and young children. [2]

Example: Haemophilus influenzae type B vaccine.

3.6.DNA Vaccines: 

DNA vaccines, still in experimental stages, show great promise in human testing. These vaccines dispense the entire organism and its parts, focusing on the essentials of the microbe's genetic material. [2]

Example: Influenza vaccine.

3.7. Recombinant Vector Vaccines: 

Recombinant vector vaccines are experimental vaccines that use an attenuated virus or bacterium to introduce microbial DNA to body cells, similar to DNA vaccines. [2]

Example: DPT

Vaccinations are crucial for family and public health, preventing the spread of dangerous diseases. The first vaccine was smallpox, which killed 300-500 million people worldwide. After being given, the disease was eradicated, making it the only disease to be completely destroyed. Vaccines can treat various diseases like Measles, Polio, Mumps, Chicken pox, Whooping cough, Diphtheria, HPV, and COVID-19. [2]

                                                                                            Figure 1: Vaccine Disease Prevention -1 [6]

                                                                                                 Figure 2: Vaccine Disease Prevention -2 [6]

5.Safety of Vaccines 

The IOM has criticized vaccine safety due to insufficient knowledge and research capacity, warning that future safety reviews will be hindered if research capacity is not improved. [5]

Clinical Issues 

Evaluation of safety & efficacy in laboratory for vaccines is equally important as other pharmaceutical products before licensure. [3]

Phase 1 trial 

• Require subjects in tens, • Detect extremely common adverse events [3]

Phase 2 trial

Enrolling numerous subjects aids in determining the correlation between antigen, Concentration and vaccine components. [3]

Phase 3 trial 

The study focuses on managing, preventing, or treating vaccine adverse events in the rudimentary stage, requiring subspecialties with adequate referral base, research funds, formulation techniques, dose effects, and common reactions. [3]

6.Methodological Problems

6.1. Signal Detection 

Surveillance systems quickly detect vaccine adverse events by examining multiple exposures and disease outcomes, with sensitivity detecting previously unknown illnesses and specificity tracking known diseases.

6.2. Standard Definitions and Evaluative Protocols – 

Case definitions are used during reporting or analysis to enhance specificity. They reduce processing times, lower operating costs, and reduce surveillance sensitivity. Open-ended reporting forms increase surveillance sensitivity and cost, but hinder scientific knowledge in immunization safety due to lack of standard case definitions.

6.3. Assessment of causality Assessment of vaccine associated adverse events is not possible unless 

Epidemiologic studies are needed to determine if vaccinated individuals are at higher risk for adverse events in the absence of vaccination.

6.4. Exposure 

Documentation of exposure status is crucial to prevent misclassification, but poor documentation due to mobility and difficulty in ascertaining vaccination status, especially in older individuals, may be encountered.

6.5. Outcome

 The Institute of Medicine committee suggests that assessing rare vaccination-related events is a major challenge, with logistical infeasibility and inadequate study power being significant obstacles.

 6.6. Analysis, Confounding and Bias 

Childhood vaccines are typically administered on schedule, but age can be a confounding factor, leading to delayed or non-vaccination due to difficult-to-control factors.

• eg: low socio-economic status.

 7.Currently Available Solutions 

7.1. Pre-licensure 

Large-scale, randomized experimental trials are needed for better vaccine risk assessment, and pre-licensure assessments should be expanded. Data and safety monitoring boards can also be improved. [3]

7.2. Post Licensure 

7.2.1. Spontaneous Reporting Systems (SRS):

Passive surveillance (SRS) is the foundation of vaccine safety monitoring systems due to low costs. Manufacturers maintain SRS for their products, which are forwarded to national regulatory authorities. The administration of vaccines leads to the development of vaccine adverse event reporting systems (VAERS), which are computerized to allow narrative descriptions of adverse events. The World Health Organization has developed guidelines for monitoring adverse events following immunization [3]

 7.3. Classifications & Case Definitions 

Vaccine adverse events can be categorized into frequency, extent, severity, causality, and preventability. [3]

7.4. Recent classification divides adverse events after vaccinations into: 

• Vaccine-induced 
• Vaccine-potentiated
• Programmatic error 
• Coincidental

7.5. Standardized Clinical Assessment Protocols & Centres: 

 Assessment of Causality Depends on: 

The strength of association, analytical bias, biologic gradient, dose response, statistical significance, consistency, and biologic plausibility/coherence are crucial factors to consider. [3]

7.6 Signal Detection

Identifying potential vaccine safety problems requires clinical intuition and epidemiologic expertise. VAERS is a large registry for rare vaccine adverse events. Bell's palsy was detected in Swiss intranasal influenza vaccine recipients. The proper reporting rate ratio (PRR) method is widely used for disproportionality in VAERS for prospective and retrospective signal generation. [3]

7.7. Mass Immunization Campaigns 

Large vaccine doses administered over short intervals can lead to more prominent clusters of vaccine adverse events. Surveillance during mass immunization campaigns generates signals, either positive or negative, and VAERS data helps identify potential risk factors for vaccine adverse events. [3]

7.8. Clinical Trials 

A) Post-licensure clinical trials 

Clinical trials optimize vaccine use by assessing changes in formulation, strain, age, dose timing, simultaneous administration, and interchangeability of vaccines from different manufacturers post-licensure. [3]

B) Phase 4 Surveillance Studies 

The system enhances the detection of adverse events not detected during pre-licensure trials and assesses potential adverse events based on spontaneous reporting systems, medical literature, or other mechanisms.

• Eg of ad-hoc follow up studies to signals of vaccine safety issues are SIDS after DTP vaccination. D) Automated Large-linked Databases

Automated large link databases could enhance the safety monitoring of post-licensure vaccine changes without conducting clinical trials. [3]

8.Methodological Approaches 

8.1. Exposures 

Vaccination records help track individual vaccine exposure, simplify study design, and assess data accuracy. Automated records streamline logistics and reduce misclassification errors. A centralized National Vaccination Registry can minimize misclassification errors. The CDC's Vaccine Identification Standards Initiative improves information transfer accuracy. [3]

 8.2. Outcomes 

A sequential approach is necessary for high sensitivity and specificity in studies, such as reviewing medical records for neurologic illness following DTP immunization and collecting and analyzing information for insidious outcomes. [3]

8.3. Analysis 

• The case cross over or case series approaches are gaining popularity in vaccine safety studies [3]

8.4. Bias 

• To minimize it is best to rely on data sources that gather information on outcomes and vaccines exposure independently [3]

9.Vaccines Pharmacovigilance:

9.1. Missing Information 

Community understanding of vaccine-preventable diseases risks children's health, loss of disease visibility, lack of urgency, fear, insufficient data, and uninformed individuals may unintentionally spread misinformation [6]. 

9.2. Misinformation 

Unintentional Misinformers and intentional Misinformers actively mislead others, often seeking personal gain. They use sophisticated tools, media's fascination with "controversies," and the internet's power. Many are unaware of diseases and misinformed about vaccine safety risks. [6]

Information about Vaccines and Vaccine Safety Missing Information Can Evolve into Misinformation

9.3. The Evolution of Missing Information into Misinformation About Vaccine Safety Issues-1 

The media raises vaccine safety concerns, leading to confusion among parents. Insufficient information from scientists prevents conclusive proof of vaccine ineffectiveness, causing further scientific uncertainty [6] 

9.4. The Evolution of Missing Information into Misinformation About Vaccine Safety Issues-2 

Public health officials compare potential risks from adverse events with known disease risks, making recommendations to protect public health. Media often reports controversy between officials and parents, with pseudoscience often discounted. New data may suggest a mechanism, but plausibility doesn't establish causality. [6]

9.5. The Evolution of Missing Information into Misinformation About Vaccine Safety Issues-3 

Scientists consensus on rejecting hypothesis, leading to parents discrediting scientists, media describing controversy, confusion, and potential disease outbreaks due to declining vaccine coverage [6]

9.6. Measles-containing Vaccines and Autism 

In 1998, UK media reported the measles vaccine as a possible cause of autism, but the public health community reassured them, and the IOM Vaccine Safety Committee rejected the association. [6]

9.7. Consequences

UK immunization levels remain low, leading to measles and mumps outbreaks in the UK, Ireland, and Germany, which spread to the US and Canada.

9.8. Thimerosal Misinformation 

Despite numerous studies and a review by the Institute of Medicine, media reports continue to controvertize a'mercury poisoning' treatment for approximately 10,000 children, with delays in immunizations and school exemptions. [4]

10.Role of The Clinician in Vaccine Safety 

Proper storage and administration, identification of contraindications, education, reporting and treatment of reactions, referral as appropriate, and follow-up are crucial aspects of proper medication management.

11. Vaccine Management 

his text covers vaccine storage, administration, dose timing, precautions, side effects management, reporting, communication, administration issues, equipment, and entry site. [11]

11.1 SPECIAL POPULATIONS should talk with a Health Care Provider before getting Flu vaccine 

Individuals with a history of severe vaccine allergies, Guillain-Barre Syndrome, moderate or severe illness, or those experiencing a pandemic may face unique considerations. [10]

11.2. Cdc Vaccine Information Statements 

Public Health law mandates parents/vaccinees to receive vaccine safety information, known side effects, contraindications, reporting adverse events, and vaccine injury compensation at each visit. [12]

11.3 WHEN IS IT SAFE TO IMMUNIZE? 

 Mild illness, disease exposure, antibiotic therapy, breastfeeding, premature birth, allergies, and family history of vaccine reactions are common factors affecting vaccination outcomes [13]

11.4 Vaccine Reactions 

Serious side effects from vaccines are rare, with only 1 to 2 people potentially experiencing severe allergic reactions if given 1 million doses [14]

11.4.1. Signs of a severe allergic reaction can include:

Breathing difficulties, face and throat swelling, fast heartbeat, a bad rash, dizziness, and weakness are common symptoms.

11.4.2. VACCINE REACTIONS What we should do: 

The process involves responding to physical, emotional, and referring needs to specialists, providing information, reassuring, reporting, and following up on the situation [15]

12. Vaccine Injury Compensation Program 

The policy covers childhood vaccines on a no-fault basis, excluding proof vaccines that caused problems or worsened existing health conditions. [16]

12.1. Pre-Licensure Testing 

 Vaccines undergo laboratory tests, animal tests, human clinical trials, and Phase I, II, and III tests to ensure safety, potency, and purity, with each lot undergoing FDA approval before release [17]

12.2. Post-Licensure Monitoring 

The VAERS, VSD Project, CISA Centers, IOM reviews, and registry of adverse events are essential for ensuring vaccine safety and promoting unified national spontaneous reporting. 

• Jointly administered by CDC and FDA since 1990 • Receives more than 20,000 reports per year 1-800-822-7967 www.vaers.hhs.gov  [18]

13.Types of Adverse Events Reported to Vaers 

• Vaccine reaction or side effect 

• Vaccine potentiated 

• Programmatic or human error 

• Coincidental

Yes, No Yes, a b c d No Illness or Syndr ome Establishing Causal Link: Adverse Event & Vaccine Vaccination VAERS = biased cell “a” [18]

14. Vaccine Safety Datalink 

Active surveillance of the US population involves 8 HMOs, covering approximately 2.5% of the population, using large-linked databases, exposure, outcomes, covariates, and scientifically rigorous hypothesis testing. [18]

15. Clinical Immunization Safety Assessment (Cisa)Centers 

The Brighton Collaboration is a clinical research organization focused on studying adverse events following immunization (AEFI), identifying risk factors, and developing evidence-based guidance for clinicians. They also develop globally accepted case definitions and guidelines for vaccine safety data. [18]

15.1. Vaccine Risk Communication 

Mercury-based preservative, thimerosal, was removed or reduced in US vaccines in 2001 due to concerns about flu vaccine safety, but no evidence of harm has been found. [18]

15.2. Why Communicate About Vaccine Risks and Benefits? 

The text states that guidance is necessary, people are seeking information, and legal requirements are being 

Met [20]

15.3. Credibility Ladder 

The list includes health professionals, safety professionals, university scientists, environmental professionals, media, activist groups, industry, federal government, and paid external consultants.

16. ADD Definition 

The CIOMS/WHO Working Group on Vaccine Pharmacovigilance defines vaccine pharmacovigilance as the science and activities related to detecting, assessing, understanding, and communicating adverse events following immunization and other vaccine-related issues, and preventing untoward effects [5]

16.1. Two type of vaccine reaction-

Minor reaction

Symptoms typically occur within hours of injection and resolve quickly. They can be local (pain, swelling, redness) or systemic (fever, malaise, muscle pain, headache, loss of appetite). [20]

Severe reaction

Vaccine-induced seizures and allergic reactions are typically non-life-threatening but can be disabling and rarely life-threatening, involving the body's reaction to a specific vaccine component.

16.2. Which AEFIs should be reported? 

Serious adverse events (AEFI) can occur due to the introduction of a new vaccine, an immunization error, unexplained events within 30 days, significant parental or community concern, and swelling, redness, or soreness at the injection site lasting more than 3 days. [20]

16.3.  Adverse event following immunization (AEFI) 

Vaccine product-related reactions include severe limb swelling after DTP vaccination, due to a defective vaccine. Quality defect reactions involve inactivated vaccines leading to paralytic polio. Immunization error reactions involve infection transmission through contaminated vials. Immunization anxiety reactions result in vasovagal syncope. Coincidental events, like fever caused by malaria, can occur. [20]

16.4 Types of ADR 

• Very common ≥ 10%

 • Common (frequent) ≥ 1% and < 10>

• Uncommon (infrequent) ≥ 0.1% and < 1>

• Rare ≥ 0.01% and < 0>

• Very rare < 0>

16.5. Determining causality 

Determining causation between events linked in time is common in drug and vaccine safety monitoring systems, especially for vaccines. Factors like missing information on "dechallenge and rechallenge," administering vaccines at coincidental age, multiple vaccines at the same visit, and specific conditions for storage, handling, transport, and administration can lead to adverse events. Therefore, investigating immunization errors is 

crucial. [21]

16.6. Rate of ADR occurrence 

The observed rate is the total number of cases reported per 1000 vaccinated children, detected in clinical trials or post-licensure vaccine safety studies. The background rate is not related to the vaccine and occurs per 1000 unvaccinated children. Vaccine reaction rate is related to the vaccine [21].

 16.7. Other factors to consider when comparing rates of AEFIs 

The text outlines the role of vaccine manufacturers, their age range, doses, case definitions, surveillance methods, and the potential differences in background conditions between communities. [21]

16.8. Problem 

A 7-year-old child died from encephalopathy, convulsions, and death during a mass measles campaign targeting 7.5 million children aged 9 months to 14 years. [21]

– Should the measles campaign be suspended? 

– Does the need for action to protect children from possible vaccine related harm in this situation outweigh the need for further investigation, or vice versa?

The immunization campaign could be discontinued, a vaccine batch could be withdrawn, and staff training and communication could be enhanced.

– Advantages: 

Along with lessening vaccine-related anxiety, the campaign also restores trust in the shot's efficacy.

– Disadvantages: 

cost, potential compromise of the campaign, loss of confidence in vaccine quality. 

The audit aims to identify immunization errors in health workers' practices, investigate training needs, and assess future evidence for reconsideration and action monitoring.

 Risk benefit evaluation 

Kanindistan has implemented a mass vaccination campaign against Japanese Encephalitis Virus (JEV) for 15-year-olds, with three million children vaccinated in the first two weeks, resulting in 140 deaths, compared to a 5.25/100,000 mortality rate in the previous year. [21]

Evaluate this information, to determine whether the risk/benefits of the JEV vaccination campaign outweigh the risks of the disease.

Comparing mortality rates of unvaccinated vs. vaccinated children

• With 3 million children vaccinated, the expected mortality in this group in a 2-week period is: 3,000,000 x 120/100,000 x 2/52 = 138 

• The number of deaths (140) is slightly higher than this figure. [21]

 Comparing the risk of children dying from Japanese Encephalitis (JE) with the excess mortality among vaccinated children  

• (140 – 138) / 3,000,000 = 1/1,500,000 vaccinated children.

 • The risk of dying from the disease (5.25/100,000) is greater than the excess mortality associated with the vaccination (1/1,500,000). [21]

17. Vaccine development: 

17.1. Steps on Vaccine Development -1 

The process involves recognizing a disease as a distinct entity, identifying the etiologic agent, growing the agent in a laboratory, establishing an animal model, identifying an immunologic correlate, inactivating or attenuating the agent, preparing a candidate vaccine, and evaluating its effectiveness. [21]

17.2. Steps on Vaccine Development -2 

The process involves preparing protocols for human studies, applying for IND approval, conducting Phase I trials, Phase II trials, and Phase III trials to evaluate safety, immugenicity, and efficacy. [21]

17.3. Steps on Vaccine Development – 3 

The process involves submitting a Product Licensure Application, Advisory Committees review, and Marketing Post-Licensure Surveillance for safety and effectiveness, taking 10-15 years, with high costs of $100-$700 million per successful vaccine [21] 

17.4. Vaccines are Not Without Risk 

No vaccine is 100% safe or effective, and all vaccines have mild to severe side effects, with the risk of disease outweighing the vaccine's risk. [21]

                                                                                                        Figure 3: Vaccine Adverse Management [21]

17.5 The Provider’s Role  

Immunization providers manage vaccine storage, administration, dose timing, precautions, side effects, reporting suspected side effects, and communicating benefits and risks, considering conditions in recipients that may compromise immunity. [21]

17.6.  Invalid Contraindications to Vaccination 

Mild illness, mild/moderate reactions, fever, antibiotic therapy, disease exposure, convalescence, pregnancy, premature birth, breastfeeding, allergies, and family history unrelated to immunosuppression. [1]

17.7.  Vaccine-Associated Paralytic Polio (VAPP)

OPV is a live attenuated virus, with 1 out of 2.4 million doses VAPP. 1997 introduced an IPV/OPV schedule, and 2000 recommended an all IPV schedule in the US.

18. Pharmacovigilance Methods 

18.1. Objective

The plan aims to establish a robust reporting system for monitoring medicine safety, understanding new medicines' safety profiles, assessing adverse drug reactions, and utilizing electronic health records for 

pharmacovigilance. [20]

18.2. Methods 

Passive surveillance

18.2.1. Spontaneous Reports

A communication from healthcare professionals to regulatory authorities outlines adverse drug reactions, identifying safety signals, rare AEs, at-risk groups, risk factors, and clinical feature.[20]

18.2.2. Case series 

Case reports can support drug-associated adverse events (AEs), generate hypotheses, and provide detailed follow-up for frequent adverse events like anaphylaxis, aplastic anemia, and Stevens-Johnson syndrome.[20]

18.3. Stimulated Reporting 

Online reporting of adverse events (AEs) encourages health professionals to report new products or limited periods, but often results in incomplete data and insufficient accuracy in incidence rates.[20]

18.3. Active surveillance

The goal is to accurately determine the number of adverse events (AEs) through a continuous, organized process, such as patient follow-ups, and to obtain comprehensive data on individual AE reports [20]

18.3.1. Sentinel Sites: -

  Active surveillance in institutions, nursing homes, and hospitals collects data on patient subgroups    and drug abuse [22]

18.3.2. Drug Event Monitoring: - 

Patients are identified through electronic prescription data or health insurance claims, and follow-up questionnaires are sent to physicians and patients, containing demographics, treatment indications, duration, dosage, clinical events, and discontinuation reasons.

Registries: - 

A registry is a list of patients with similar characteristics, such as disease, drug, or pregnancy registry, which differs depending on the patient type.

18.4. Comparative Observational Studies: -

Traditional epidemiologic methods are crucial for assessing adverse events (AEs), while observational study designs validate signals from spontaneous reports or case series [20]

18.4.1. Cross Sectional Studies: -

Data from a single point in time, collected for surveys or ecological analysis, is best used to examine disease prevalence or trends over time when serial data is captured. [20]

18.4.2. Case Control Study: - 

The study identifies a disease, selects controls or patients without the disease or event, and compares their exposure status using odds ratio. [20]

18.4.3. Cohort Study: - 

The study follows a population at risk for a disease, tracking exposure status and incident rates. It selects cohorts based on drug use and investigates multiple adverse events [20]

18.5. Targeted Clinical Investigations: -

Significant risks from pre-approval clinical trials may prompt further studies to evaluate ADR mechanisms, conduct PK and PD studies, and investigate potential drug-drug and food-drug interactions.

18.6. Descriptive Studies: -

This method is primarily used to determine the background rate of outcome events and/or the prevalence of drug use in specific populations.

18.7. Natural History of Disease- 

The study analyzed the natural history of disease, patient characteristics, disease distribution, and potential outcomes' incidence and prevalence in selected populations.

18.8. Drug Utilization Study- 

Studies collect data on specific populations like the elderly, children, and patients with hepatic or renal dysfunction, often stratified by age, gender, medication, and other factors.

19. Adverse Event Communication Vincent, Covello. (2003) 

Respect the opinions of those who believe they have been harmed by immunization. If an adverse event is unfounded, provide a sympathetic explanation. Acknowledge uncertainty, be open about an event, discuss prevention measures, and report all suspected adverse events to the Vaccine Adverse Event Reporting System.

Vaccines have been instrumental in eradicating diseases like smallpox and reducing the prevalence of others like polio and measles, saving millions of lives and improving public health worldwide. They also contribute to herd immunity, protecting vulnerable populations like infants, elderly, and immunocompromised individuals. Pharmacovigilance is a crucial aspect of vaccine research, development, and post-marketing surveillance, involving the detection, assessment, understanding, and prevention of adverse effects or vaccine-related concerns. Governments, regulatory bodies, manufacturers, healthcare professionals, and patients all contribute to pharmacovigilance by reporting adverse events and participating in surveillance activities.